



MOMENTA

Momenta Pharmaceuticals Announces Date of Third Quarter 2018 Financial Results Conference Call and Webcast

October 31, 2018

CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will release its financial results for the third quarter ended September 30, 2018 and provide a corporate update before the U.S. financial markets open on Wednesday, November 7, 2018.

Management will host a conference call on November 7, 2018 at 8:00 a.m. ET to discuss these results and provide an update on the company. To access the call, please dial (877) 224-9084 (domestic) or (720) 545-0022 (international) prior to the scheduled conference call time and provide the access code 3079348. A live webcast of the call will be available on the "Investors" section of the company's website, www.momentapharma.com. An archived version of the webcast will be posted on the Momenta website approximately two hours after the call.

About Momenta

Momenta is a biotechnology company with a validated innovative scientific platform focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Momenta's lead product candidate, M281, is a potentially best-in-class anti-FcRn antibody; M254, is a hyper-sialylated human immunoglobulin (hslgG) designed as a high potency alternative to intravenous immunoglobulin (IVIg); and M230 (CSL730), is a potential first-in-class novel recombinant Fc multimer being developed in collaboration with CSL. Momenta also has a focused pipeline of two biosimilar candidates: M710, a proposed biosimilar to EYLEA[®] being developed in collaboration with Mylan, and M923, Momenta's wholly-owned proposed biosimilar to HUMIRA[®]. Momenta's two FDA-approved complex generic products, enoxaparin sodium injection and Glatopa[®] (glatiramer acetate injection), are marketed by its collaboration partner, Sandoz.

To receive additional information about Momenta, please visit the website at www.momentapharma.com, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Contact:

Sarah Carmody
Momenta Pharmaceuticals
1-617-395-5189
IR@momentapharma.com



MOMENTA

Source: Momenta Pharmaceuticals, Inc.